Biologics Commonly Used in Cutaneous Crohn's Disease - Summary - MDSpire

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.

  • By

  • Andrea Surnit

  • May 27, 2026

  • 3 min

Share

Objective:

To evaluate the outcomes of biologic or small-molecule inhibitor therapy in patients with cutaneous Crohn's disease (CCD).

Key Findings:
  • Include the terminal ileum as the most commonly involved gastrointestinal site.
  • Add the percentages of patients with no inflammatory bowel disease diagnosis, ulcerative colitis, and indeterminate colitis.
Interpretation:

Remove unsupported conclusions about treatment efficacy and timing.

Limitations:
  • Expand on the variability in treatment regimens across patients and centers.
Conclusion:

This study contributes to the limited literature on cutaneous Crohn's disease.

Original Source(s)

Biologics Commonly Used in Cutaneous Crohn's Disease

  • by Andrea Surnit

  • May 27, 2026

Related Content

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.